Sanuwave Q3 2026 slides show 24% revenue drop, system sales plunge

Sanuwave Health (SNWV) reported a 24% revenue decline to $8.6M in Q3 2026, missing expectations. Operating loss of $1.1M compared to prior-year income. System sales dropped 74% YoY, while consumables grew 2%. CMS rule changes disrupted the wound care market. Shares rose 8.51% premarket despite challenges, reflecting long-term hospital strategy focus.

Original reporting
Published Nov 11, 2026, 2:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 11, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$SNWV
Bearish
high confidence
Mentioned
$SNWV
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$SNWVBearishMed
01

Why it matters

The disclosure combines a large top-line decline, a sharp drop in Ultramist system unit sales, and a swing to operating loss, while also outlining reimbursement-related changes and a shift toward hospital/facility sales.

02

Market read

Traders can reassess near-term revenue trajectory and financing risk after the Q3 print and covenant update, while also repricing longer-term reimbursement tailwinds.

03

What to watch

The article notes a debt covenant non-compliance that was later amended and waived, which can matter for near-term financing risk and equity overhang.

Relevance 8/10Novelty 8/10Timing: premarket reaction to the Q3 2026 business update on Nov 11

Background

Sanuwave’s Q3 2026 update attributes market disruption to a CMS proposed rule announced in July, which management says drove mobile wound-care providers to exit.

Company-level read

Ticker impact

$SNWVBearishHigh confidence
Context

Sanuwave reported Q3 2026 revenue down 24% to $8.6M, with system sales collapsing and an operating loss after CMS reimbursement disruption.

Expected impact

Likely continued volatility, with downside risk if system sales weakness persists and upside limited by longer hospital sales cycles.

Evidence & confidence

The article discloses a large revenue and operating-income deterioration plus a specific driver (CMS rule disruption) and a concrete offset (hospital pivot and reimbursement packaging change).

Market effects

Highlights reimbursement-rule sensitivity for wound-care medical device providers and the risk of secondary-market undercutting for capital equipment.

No specific regional impact described beyond rural provider exits.

Primarily US reimbursement policy driven, with limited direct global read-through.

Counterpoint

The consumables resilience and hospital-channel pivot could stabilize cash burn if utilization in the installed base holds, offsetting system placement delays.

Key entities

  • Sanuwave Health

    NASDAQ-listed wound care medical device company reporting Q3 2026 results and strategy pivot.

  • Centers for Medicare & Medicaid Services (CMS)

    US agency whose proposed reimbursement rule is cited as the primary driver of market disruption.

  • JPMorgan Chase Bank, N.A.

    Counterparty to Sanuwave’s credit agreement referenced in covenant compliance discussion.

Related articles

$SNWVMed

Sanuwave Announces Q3 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q3 FY2026 Financial Results Q3 2026 revenues were $8.6 million, down 24% from $11.3 million in Q3 2025. Q3 2026 gross margin was 77.3%, versus 77.6% in Q3 2025. GAAP operating loss was $1.1 million for Q3 2026 versus operating income of $0.9 millio

$SNWVMedAI 8/10

SANUWAVE (SNWV) Q2 2026 Earnings Call Transcript

SANUWAVE (SNWV) reported Q2 2026 revenue of $9.7M, down 3% from $10.1M, driven by lower capital equipment sales. UltraMIST applicator revenue rose 13% to $7.3M, while UltraMIST system revenue fell 34% to $2.3M. The company posted a $0.7M net loss and withdrew FY2026 guidance amid proposed 2027 Medicare reimbursement cuts.

$SNWVMed

Sanuwave Announces Q2 FY2026 Financial Results

SANUWAVE Health, Inc. (SNWV) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Sanuwave Announces Q2 FY2026 Financial Results Q2 2026 revenues were $9.7 million, down 3% from $10.1 million in Q2 2025. Q2 2026 gross margin was 76.2%, versus 78.1% in Q2 2025. GAAP Operating (Loss) Income was $(0.3) million for Q2 2026 versus $1.4 million in Q2 20

$SNWVMedAI 8/10

What's Going On With SANUWAVE Health Stock On Friday? - SANUWAVE Health (NASDAQ:SNWV)

Sanuwave Health (NASDAQ:SNWV) said it expects Q2 2026 revenue of $9.6 million to $9.8 million, above prior guidance of $8.5 million to $9.5 million. The company noted Q2 revenue is about 3% to 5% lower year over year from $10.1 million. It cited pressured capital sales but record consumable applicator momentum and offered trade-in and support programs. Shares were down 4.44% to $6.36.